Table 5.

Best hematologic and organ response to treatment

Hematologic response-evaluable patientsPI-naive cohort, n = 5 (%)PI-exposed cohort, n = 16 (%)RP2/3D cohort, N = 21 (%)
ORR 5 (100) 6 (38) 11 (52) 
 CR 2 (40) 2 (10)* 
 VGPR 3 (60) 4 (25) 7 (33) 
 PR 2 (13) 2 (10)* 
No change 9 (56) 9 (43) 
Progressive disease 1 (6) 1 (5) 
Hematologic response-evaluable patientsPI-naive cohort, n = 5 (%)PI-exposed cohort, n = 16 (%)RP2/3D cohort, N = 21 (%)
ORR 5 (100) 6 (38) 11 (52) 
 CR 2 (40) 2 (10)* 
 VGPR 3 (60) 4 (25) 7 (33) 
 PR 2 (13) 2 (10)* 
No change 9 (56) 9 (43) 
Progressive disease 1 (6) 1 (5) 
Organ response-evaluable patientsPI-naïve cohort, n = 5 (%)PI-exposed cohort, n = 13 (%)RP2/3D cohort, N = 18 (%)
Response 5 (100) 5 (38) 10 (56) 
 Cardiac response 2/3 (67)§ 3/8 (38) 5/11 (45) 
 Renal response 3/3 (100) 2/8 (25) 5/11 (45) 
No change 8 (62) 8 (44) 
Progression 
Organ response-evaluable patientsPI-naïve cohort, n = 5 (%)PI-exposed cohort, n = 13 (%)RP2/3D cohort, N = 18 (%)
Response 5 (100) 5 (38) 10 (56) 
 Cardiac response 2/3 (67)§ 3/8 (38) 5/11 (45) 
 Renal response 3/3 (100) 2/8 (25) 5/11 (45) 
No change 8 (62) 8 (44) 
Progression 

ORR indicates overall response rate; CR, complete response; PR, partial response; VGPR, very good partial response.

*

One patient received dexamethasone.

Two patients received dexamethasone.

According to NT-proBNP levels in 11 response-evaluable patients with cardiac involvement at baseline.

§

One additional patient had a cardiac response by echo.

Assessed retrospectively by updated renal response criteria36  in 11 response-evaluable patients with renal involvement at baseline.

or Create an Account

Close Modal
Close Modal